Two China biotechs drop U.S. IPO plans for $800 million Hong Kong floats: sources

HONG KONG (Reuters) – Two Chinese biotechs have axed plans to list in New York and instead aim to raise up to $800 million in Hong Kong IPOs, seeking to cash in on new rules to woo early-stage drug developers, sources said. Fidelity Investments-backed …
( read original story …)


Related Post

250 live geckos from Hong Kong seized by Customs a...
views 10
MANILA, Philippines — The Bureau of Customs (BOC) ...
Losses May Accelerate For Hong Kong Stock Market
views 11
Among the actives, China Petroleum and Chemical (S...
Hong Kong Bourse Tipped To Open Higher
views 10
BOC Hong Kong skidded 0.89 percent, New World Deve...
Man Who Bared `Enigma Network’ Has New Hong ...
views 18
(Bloomberg) -- His last big warning to investors, ...
Alibaba-backed Hong Kong AI lab names first batch ...
views 17
A Hong Kong artificial intelligence lab backed by ...
Briefing: Alibaba and SenseTime-backed Hong Kong A...
views 17
What happened: A Hong Kong artificial intelligence...
Hong Kong: HANG SENG INDEX (.HSI) little changed e...
views 23
After Wednesday’s holiday and strong regional gain...
Hong Kong man sentenced to 1 year in jail for voye...
views 22
Lap Kwan Yue, 19, will spend one year behind bars....
Hong Kong Vs. Singapore: Which Stock Market Has Be...
views 23
So how can it be that the HSI so handily outperfor...
Tencent partners with HK property developer SHKP t...
views 24
Internet giant Tencent Holdings Ltd and Hong Kong ...